Anginovag spray oromucosal

Kraj: Armenia

Język: angielski

Źródło: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

Składnik aktywny:

dequalinium (dequalinium chloride), tyrothricin, enoxolone, hydrocortisone (hydrocortisone acetate), lidocaine (lidocaine hydrochloride)

Dostępny od:

Ferrer Internacional

Kod ATC:

առկա չէ (R02A)

INN (International Nazwa):

dequalinium (dequalinium chloride), tyrothricin, enoxolone, hydrocortisone (hydrocortisone acetate), lidocaine (lidocaine hydrochloride)

Dawkowanie:

1mg/ml+ 4mg/ml+ 0.6mg/ml+ 0.6mg/ml+ 1mg/ml

Forma farmaceutyczna:

spray oromucosal

Sztuk w opakowaniu:

20ml (200 doses) plastic container and pump dispenser

Typ recepty:

OTC

Status autoryzacji:

Registered

Data autoryzacji:

2020-12-30

Charakterystyka produktu

SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE MEDICINAL PRODUCT
ANGINOVAG Oromucosal spray solution
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Composition per 1 ml :
Dequalinium chloride
....................................................................................................................
1,0 mg
Enoxolone
.......................................................................................................................................
0,6 mg
Hydrocortisone acetate
..................................................................................................................
0,6 mg
Tyrothricin
......................................................................................................................................
4,0 mg
Lidocaine hydrochloride
................................................................................................................
1,0 mg
Excipient(s) with known effect :
Propylene glycol and ethanol 96%
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Oromucosal spray solution.
Clear, colourless or slightly yellow solution
4.
CLINICAL PARTICULARS
4.1
Therapeutic indications
Preventive and curative therapy of oropharyngeal affections:
Amygdalitis, pharyngitis, laryngitis, stomatitis, oral ulcers and
aphthae, glossitis.
4.2
Posology and method of administration
Posology
Oropharyngeal use.
Adults and children over 13 years old
Attack dose: 1-2 applications every 2-3 hours.
Maintenance or preventive dose: One application every 6 hours.
Paediatric population
The safety and efficacy of Anginovag in children aged under 13 years
old have not yet been
established.
Method of administration
Open the mouth widely. Point the inhaler mouthpiece to the affected
area (throat, mouth, tongue, etc,
depending on the case).
Push the upper part of the cap from top to bottom up to the limit,
keeping the bottle in upright position.
The bottle is supplied with a metering valve: each actuation up to the
limit causes the regulated drug
delivery.
4.3
Contra